Boxer Capital Management LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Boxer Capital Management LLC purchased a new stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 466,680 shares of the company's stock, valued at approximately $10,864,000. Boxer Capital Management LLC owned about 0.91% of Spyre Therapeutics as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Barclays PLC boosted its position in shares of Spyre Therapeutics by 64.7% in the third quarter. Barclays PLC now owns 105,467 shares of the company's stock valued at $3,101,000 after acquiring an additional 41,424 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Spyre Therapeutics in the 4th quarter valued at $290,000. Victory Capital Management Inc. acquired a new stake in Spyre Therapeutics in the 4th quarter worth $6,241,000. JPMorgan Chase & Co. increased its holdings in shares of Spyre Therapeutics by 19.6% during the 4th quarter. JPMorgan Chase & Co. now owns 35,248 shares of the company's stock worth $821,000 after purchasing an additional 5,775 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Spyre Therapeutics by 78.7% during the third quarter. Jane Street Group LLC now owns 20,641 shares of the company's stock valued at $607,000 after buying an additional 9,090 shares during the last quarter. Institutional investors own 80.39% of the company's stock.

Spyre Therapeutics Stock Performance

Spyre Therapeutics stock traded down $1.58 during trading hours on Tuesday, hitting $12.51. 483,362 shares of the stock were exchanged, compared to its average volume of 599,690. The stock has a market capitalization of $754.05 million, a P/E ratio of -1.67 and a beta of 2.78. The business's 50-day moving average is $15.81 and its two-hundred day moving average is $22.54. Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $40.49.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.08. On average, equities analysts predict that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on SYRE. Wedbush restated an "outperform" rating and set a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday. The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 18th. Leerink Partnrs raised shares of Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, April 8th. Wolfe Research assumed coverage on shares of Spyre Therapeutics in a report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 price objective for the company. Finally, Leerink Partners began coverage on shares of Spyre Therapeutics in a research note on Tuesday, April 8th. They issued an "outperform" rating and a $45.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Spyre Therapeutics currently has a consensus rating of "Buy" and an average price target of $49.57.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).